Journal of Allergy and Clinical Immunology-In Practice最新文献

{"title":"Decision Aid for Pediatric Atopic Dermatitis.","authors":"Anna B Fishbein, Karen Kaiser, Sarah B Welch, Catherina Lu, Jack Osborn, Jessica Thomas, Michelle Taddeo, Hosanna An, Andie Kwon, George Luong, Kenneth L Zhang, Stephanie M Rangel, Amy S Paller, James W Griffith","doi":"10.1016/j.jaip.2025.01.030","DOIUrl":"10.1016/j.jaip.2025.01.030","url":null,"abstract":"<p><strong>Background: </strong>Atopic dermatitis is a common chronic skin disease that involves frequent physician visits and often complex care plans. Despite the expanding therapeutic options, there is no existing decision aid to guide patients, families, and clinicians through treatment options.</p><p><strong>Objective: </strong>Our objective was to develop an evidence-based decision aid that would be widely accepted for shared decision-making in pediatric atopic dermatitis.</p><p><strong>Methods: </strong>Per rigorous International Patient Decision Aid Standards, the following steps were taken: (1) literature review; (2) focus groups with patients and caregivers; (3) expert interviews; (4) prototype creation, revision, and pilot testing in the clinic; and (5) further in-clinic testing.</p><p><strong>Results: </strong>Six focus groups provided insight into patient/parent preferences (n = 32) regarding treatment experiences and preferences. Nine expert interviews revealed implementation strategies for shared decision-making, eliciting themes of communication, patient education, challenges to and supports for treatment adherence, useful materials/resources, and other strategies for success. Using content from literature review, patient/parent focus groups, and expert interviews, a draft decision aid was systematically created. Cognitive interviews (n = 10) with patients/parents resulted in tool refinement. In-clinic testing demonstrated that the tool was helpful; an average ± standard deviation score was 7.8 ± 1.7 (0-10 scale, n = 18). A final decision aid was produced.</p><p><strong>Conclusions: </strong>A decision aid for children with atopic dermatitis can be used for clinical encounters and has the potential to improve patient/family engagement in decision-making. In addition, we include a worksheet on patient/parent values and an eczema action plan for implementation. Efficacy of this tool will be tested across populations in future studies.</p>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"The long road\" of caring for a child with severe combined immunodeficiency: A qualitative study.","authors":"Kirrilly M Pursey, Kahn Preece, Emma Burden, Rani Bhatia","doi":"10.1016/j.jaip.2025.01.031","DOIUrl":"10.1016/j.jaip.2025.01.031","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying Precise Disparities Among Persons With Inborn Errors of Immunity","authors":"Roxanna Farzad MS ,&nbsp;Jacob Blaukovitch MA ,&nbsp;Nicholas L. Rider DO","doi":"10.1016/j.jaip.2024.12.009","DOIUrl":"10.1016/j.jaip.2024.12.009","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 2","pages":"Pages 396-397"},"PeriodicalIF":8.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143319381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Climate Change on Allergen and Irritant Exposure","authors":"","doi":"10.1016/j.jaip.2025.01.002","DOIUrl":"10.1016/j.jaip.2025.01.002","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 2","pages":"Page 274"},"PeriodicalIF":8.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143319557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Empiric elimination diets for eosinophilic esophagitis: Barriers, facilitators, and impact on quality of life","authors":"Pooja Mehta MD, MSCS ,&nbsp;Zhaoxing Pan PhD ,&nbsp;Glenn T. Furuta MD ,&nbsp;Kara Kliewer RD, PhD","doi":"10.1016/j.jaip.2024.10.030","DOIUrl":"10.1016/j.jaip.2024.10.030","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 2","pages":"Pages 434-436"},"PeriodicalIF":8.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Treatment Response to Mepolizumab Predicts Clinical Remission in Severe Eosinophilic Asthma","authors":"Yuto Hamada MD, PhD ,&nbsp;Peter G. Gibson FRACP, DMed ,&nbsp;Erin S. Harvey PhD ,&nbsp;Sean Stevens MBiostat ,&nbsp;Hayley Lewthwaite PhD ,&nbsp;Michael Fricker PhD ,&nbsp;Vanessa M. McDonald PhD ,&nbsp;Andrew Gillman FRACP ,&nbsp;Mark Hew FRACP, PhD ,&nbsp;Vicky Kritikos PhD ,&nbsp;John W. Upham MBBS, FRACP, PhD ,&nbsp;Dennis Thomas PhD","doi":"10.1016/j.jaip.2024.10.041","DOIUrl":"10.1016/j.jaip.2024.10.041","url":null,"abstract":"<div><h3>Background</h3><div>Mepolizumab can induce an early response and clinical remission in people with severe eosinophilic asthma (SEA).</div></div><div><h3>Objective</h3><div>To find whether early response to mepolizumab (100 mg) could predict future asthma remission and to identify the best predictor of treatment response to mepolizumab for achieving remission.</div></div><div><h3>Methods</h3><div>The Australian Mepolizumab Registry was used to investigate the early response to mepolizumab at 3 and 6 months and relate this to clinical remission at 12 months. Treatment response was assessed using the 5-item Asthma Control Questionnaire (ACQ-5), oral corticosteroid (OCS) dose, exacerbation frequency, and postbronchodilator FEV₁. Clinical remission, assessed at 12 months, was defined as an ACQ-5 score less than or equal to 1.0 at 12 months, no exacerbations in the previous 6 months, and no OCS use for asthma in the previous 6 months. We estimated the optimism-corrected area under the curve for internal validation.</div></div><div><h3>Results</h3><div>We analyzed 255 participants with SEA. Seventy-eight (30.6%) participants achieved clinical remission at 12 months. A prediction model including ACQ-5 score, exacerbation frequency, OCS dose, and postbronchodilator FEV₁ at 6 months was more predictive of achieving remission than measures at 3 months. The ACQ-5 score at 6 months had the highest optimism-corrected area under the curve of 0.778 (95% CI, 0.719-0.833). An ACQ-5 score less than 1.5 at 6 months had a sensitivity of 85.9% for achieving clinical remission, whereas an ACQ-5 score less than 0.75 had a specificity of 84.7%.</div></div><div><h3>Conclusions</h3><div>The ACQ-5 score at 6 months was the best predictor of achieving clinical remission at 12 months in people with SEA treated with mepolizumab. These results can be used to design a treat-to-target paradigm for asthma, in which treatment response is assessed at 6 months to predict clinical remission.</div></div>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 2","pages":"Pages 333-342.e9"},"PeriodicalIF":8.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142632002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sirolimus as a possible treatment in cleavage-resistant RIPK1-induced autoinflammatory syndrome","authors":"Marco Cattalini MD ,&nbsp;Manuela Cortesi MD ,&nbsp;Manuela Baronio PhD ,&nbsp;Antonella Insalaco MD ,&nbsp;Fabrizio de Benedetti MD ,&nbsp;Vassilios Lougaris Prof ,&nbsp;Raffaele Badolato Prof","doi":"10.1016/j.jaip.2024.11.003","DOIUrl":"10.1016/j.jaip.2024.11.003","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 2","pages":"Pages 430-433.e1"},"PeriodicalIF":8.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142668822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Effectiveness of Lanadelumab in Hereditary Angioedema: Multicountry INTEGRATED Observational Study","authors":"Markus Magerl MD ,&nbsp;Laurence Bouillet MD, PhD ,&nbsp;Inmaculada Martinez-Saguer PhD, MD ,&nbsp;Francois Gavini MSc ,&nbsp;Nawal Bent-Ennakhil MSc ,&nbsp;Laura Sayegh MSc ,&nbsp;Irmgard Andresen MD","doi":"10.1016/j.jaip.2024.12.008","DOIUrl":"10.1016/j.jaip.2024.12.008","url":null,"abstract":"<div><h3>Background</h3><div>Hereditary angioedema (HAE) is a rare genetic disease characterized by recurrent episodes of cutaneous or subcutaneous edema. There is clinical need for treatments that reduce the rate of HAE attacks in patients.</div></div><div><h3>Objectives</h3><div>Primary objectives were to evaluate the effectiveness of lanadelumab on attack-free rate (AFR; proportion of patients who had zero HAE attacks), and of every 2-week and every 4-week adjustments on AFR.</div></div><div><h3>Methods</h3><div>A retrospective medical chart review study was conducted in 19 HAE centers and included data from patients with type I or II HAE treated with lanadelumab (index treatment) in Germany, France, Greece, and Austria who were aged 12 years or older (ClinicalTrials.gov identifier: NCT04861090). Data abstraction occurred September 15, 2021, to June 29, 2022. Analyses were primarily descriptive.</div></div><div><h3>Results</h3><div>Data from 198 patients were collected (61.6% female, 91.9% with type I HAE). Lanadelumab treatment patterns varied between countries. Cumulative AFR improved from 0% (preindex) to 54.4% (12 months postindex) and 39.4% (postindex; median duration, 28.8 months). Monthly AFRs varied from 16.2% to 28.3% preindex (17.7% AFR in the month before index date), and from 82.7% (month 1) to more than 95% at multiple time points between 26 and 43 months postindex. Patients with interval increases (n = 144 [72.7%]) showed improved cumulative AFR (0% preindex to 50.0% postindex).</div></div><div><h3>Conclusions</h3><div>This real-world study demonstrates that lanadelumab long-term prophylaxis is effective in improving AFR in patients with type I/II HAE on every 2-week dosing and dose interval increases. Effectiveness with lanadelumab is rapid and was observed starting from the first month of starting therapy.</div></div>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 2","pages":"Pages 378-387.e2"},"PeriodicalIF":8.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mold Remediation in Homes After Flooding","authors":"Amber Hardeman MD, MPH, MBA ,&nbsp;Erin C. Lindgren ,&nbsp;John C. Carlson MD, PhD","doi":"10.1016/j.jaip.2024.12.018","DOIUrl":"10.1016/j.jaip.2024.12.018","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 2","pages":"Pages 289-294"},"PeriodicalIF":8.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emergency visits for childhood asthma exacerbations are linked to socioeconomic factors","authors":"Bruno Mahut MD ,&nbsp;Jeanne Pergeline MD ,&nbsp;Plamen Bokov MD, PhD ,&nbsp;Nicole Beydon MD ,&nbsp;Aurélie Bourmaud MD, PhD ,&nbsp;Christophe Delclaux MD, PhD","doi":"10.1016/j.jaip.2024.10.028","DOIUrl":"10.1016/j.jaip.2024.10.028","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 2","pages":"Pages 424-426.e1"},"PeriodicalIF":8.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142565236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}